| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA747: Nintedanib for treating progressive fibrosing interstitial lung disease |
|
Medicine details |
|
| Medicine name | nintedanib (Ofev®) |
| Formulation | capsule |
| Reference number | 3759 |
| Indication | Treatment of chronic fibrosing interstitial lung diseases in adults with a progressive phenotype |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/09/2020 |
| NICE guidance | TA747: Nintedanib for treating progressive fibrosing interstitial lung disease |